132 results
8-K
EX-1.1
CRNX
Crinetics Pharmaceuticals Inc
21 Jun 24
Other Events
5:24pm
filed as exhibits to the Registration Statement or described in the Registration Statement and the Prospectus.
(q) Independent Accountants. BDO USA, LLP … , who has audited or reviewed certain financial statements of the Company and its subsidiaries, is an independent registered public accounting firm
S-3ASR
EX-23.1
CRNX
Crinetics Pharmaceuticals Inc
21 Jun 24
Automatic shelf registration
4:45pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Prospectus
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
21 Jun 24
Automatic shelf registration
4:45pm
statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources … and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data
8-K
CRNX
Crinetics Pharmaceuticals Inc
10 Jun 24
Submission of Matters to a Vote of Security Holders
4:30pm
- Ratification of Selection of Independent Registered Accounting Firm
The Company’s stockholders ratified the selection of BDO USA, P.C … . as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2024. The results of such vote were:
Votes For
Votes Against
DEFA14A
CRNX
Crinetics Pharmaceuticals Inc
25 Apr 24
Additional proxy soliciting materials
4:48pm
To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending … % FOR WITHHOLD FOR FOR FOR AGAINST ABSTAIN 2. To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered
S-3ASR
jb8w25bbldw
19 Mar 24
Automatic shelf registration
4:05pm
S-3ASR
EX-23.1
87138 dhbgq
19 Mar 24
Automatic shelf registration
4:05pm
8-K
EX-99.2
dx72xteki8yvyz
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
w9ubr
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-10.2
a8pqh8t1
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
S-8
EX-23.2
sdbzveyaoaspnkd
28 Feb 24
Registration of securities for employees
6:04pm
S-8
bbm4nzo5sedqslafk8
28 Feb 24
Registration of securities for employees
6:04pm
8-K
EX-99.1
ih12tki9h
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
zs0r i7bfe79o8t
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
z61kgvx3rxu tswrco
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
S-8
2puzut1ks72ezvh 9r21
7 Nov 23
Registration of securities for employees
4:31pm